Effect of budesonide combined with aerosol inhalation of terbutaline in treating bronchial asthma children

Objective To observe the effect of budesonide combined with aerosol inhalation of terbutaline in children with bronchial asthma and the influence on serum cyclooxygenase-2(COX-2)and chemokine like factor-1(CKLF-1). Methods A total of 100 children with bronchial asthma were selected as study objects, and were divided into two groups according to random number table method, with 50 cases in each group. The control group was treated with budesonide, and the observation group was treated with aerosol inhalation of terbutaline based on the control group. Treatment effect, symptom relief time and hospitalization time were compared. The changes of forced vital capacity(FVC), forced expiratory capacity in the first second(FEV₁), ratio of forced expiratory capacity in the first second to forced vital capacity(FEV₁/FVC), COX-2, CKLF-1 before and after treatment in two groups were recorded, and the occurrence of adverse reactions of two groups was recorded. Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05). Children in the observation group had shorter improvement time in chest tightness, wheezing, cough and hospitalization time than the control group(P<0.05). Compared with before treatment, the levels of FVC, FEV₁, FEV₁/FVC in two groups were all increased, and the observation group was higher than the control group, the differences were statistically significant(P<0.05). After treatment, the expression levels of COX-2 and CKLF-1 in the two groups were significantly lower than before treatment, and the observation group was significantly lower than - the control group(P<0.05). The incidence rate of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). Conclusion Budesonide combined with atomization inhalation of terbutaline can effectively alleviate the clinical symptoms of children with bronchial asthma, reduce the expression levels of serum COX-2 and CKLF-1, promote the recovery of lung function, and shorten the hospitalization time.